ClinicalTrials.gg
CompletedNCT04538794Updated Jul 19, 2023

A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria

A Phase 1 interventional study of CDX-0159 and Normal Saline in Chronic Spontaneous Urticaria, sponsored by Celldex Therapeutics. Completed at 14 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-07-19.

Sponsored by Celldex Therapeutics · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jan 2023, 3 years 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 64 studies in Chronic Urticaria with a site in United States — 9 open to participants now, 17 under way, 6 of them phase 3. Chronic Urticaria · United States.

Enrollment
43rd of 58
45 · median 132
Started
2020
with 2 others
Phase 1
5 of 64
1 open now
Registered
28th of 64
by date
Lead sponsor
5 of 64
Celldex Therapeutics

Among the 64 studies in Chronic Urticaria with a site in United States, this one is the 43rd largest by enrollment of the 58 interventional ones that give a count, is one of 3 that started in 2020, is one of 5 in phase 1, and was the 28th registered.

Chronic Urticaria

197 studies on the registry are indexed under Chronic Urticaria; 48 are open to participants now.

Browse Chronic Urticaria studies →

Open to participants now

9 of the 64 studies in Chronic Urticaria with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 25 Chronic Urticaria studies recruiting now, 11 (44%) set no upper age limit and 10 (40%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Chronic Urticaria with a site in United States, or all of them as a file.
02

Study summary

This is a study to determine the safety of multiple doses of CDX-0159 in patients with Chronic Spontaneous Urticaria.

Read the detailed description

The purpose of the study is to explore the safety, pharmacodynamics, and pharmacokinetics of ascending doses of CDX-0159 in patients with Chronic Spontaneous Urticaria who remain symptomatic despite treatment with antihistamines.

There is a screening period of up to 2 weeks, a 12-week double-blind treatment period and a 12-week follow-up period after treatment. Patients will receive multiple doses of CDX-0159 or placebo as add on therapy to their antihistamine.

03

Conditions studied

  • Chronic Spontaneous Urticaria

Browse trials for

Keywords

  • CDX-0159
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Males and females, 18 - 75 years old.
  2. Diagnosis of chronic spontaneous urticaria (CSU) despite the use of H1-antihistamines alone or in combination with H2-antihistamines and/or leukotriene receptor antagonists, as defined by:

    1. Diagnosis of CSU for >/= 6 months.
    2. The presence of itch and hives for >/= 6 consecutive weeks at any time prior to Visit 1 despite current use of H1-antihistamines.
    3. UAS7 of >/= 16 and HSS7 of >/= 8 during the 7 days before treatment
    4. In-clinic UAS >/= 4 on one of the screening visit days
    5. Use of H1-antihistamines alone or in combination with H2-antihistamines and/or leukotriene receptor antagonists for at least 3 days immediately prior to study entry and throughout the study.
  3. Other than CSU, have no other significant medical conditions that would cause additional risk or interfere with study procedures.
  4. Normal blood counts and liver function tests.
  5. Both males and females of must agree to use highly effective during the study and for 150 days afterwards after treatment.
  6. Willing and able to complete a daily symptom electronic diary for the duration of the study and adhere to the study visit schedule.

Key Exclusion Criteria:

  1. Women who are pregnant or nursing.
  2. Cleary defined cause for chronic urticaria.
  3. Known , or infection.
  4. Vaccination with a within 4 weeks prior to study drug administration (subjects must agree to avoid vaccination during the study). Inactivated vaccines are allowed such as seasonal influenza for injection.
  5. History of anaphylaxis.

There are additional criteria that your study doctor will review with you to confirm you are eligible for the study.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    CDX-0159

    CDX-0159 every 4-8 weeks

    Drug: CDX-0159

  • Placebo comparator
    Normal Saline

    Normal saline every 4-8 weeks

    Drug: Normal Saline

Interventions

  • Administered intravenously

  • DrugNormal Saline

    Administered intravenously

06

What researchers measure

Primary outcomes

  1. Safety as assessed by the incidence and severity of adverse events

    Safety of multiple, ascending doses of CDX-0159 as determined by drug related adverse events

    Time frame: From Day 1 (first dose) to Day 169 (last follow-up visit)

Secondary outcomes

  1. Pharmacokinetic evaluation

    CDX-0159 serum concentrations will be measured at specified visits

    Time frame: From Day 1 (before first dose) to Day 169 (last follow-up visit)

  2. Pharmacodynamic evaluation

    The change from baseline for Urticaria Activity Score (UAS7) in patients who received CDX-0159 vs. placebo

    Time frame: From Day 1 (first dose) to Day 169 (last follow-up visit)

  3. Pharmacodynamic evaluation

    The change from baseline for Hives Severity Score (HSS7) in patients who received CDX-0159 vs. placebo

    Time frame: From Day 1 (first dose) to Day 169 (last follow-up visit)

  4. Pharmacodynamic evaluation

    The change from baseline for Itch Severity Score (ISS7) in patients who received CDX-0159 vs. placebo

    Time frame: From Day 1 (first dose) to Day 169 (last follow-up visit)

  5. Pharmacodynamic evaluation

    The change in baseline for Urticaria Control Test (UCT) in patients who received CDX-0159 vs. placebo

    Time frame: Day 1 (first dose) to Day 169 (last follow up visit)

  6. Pharmacodynamic evaluation

    The effect of CDX-0159 on stem cell factor levels

    Time frame: From Day 1 (before first dose) to Day 169 (last follow-up visit)

  7. Pharmacodynamic evaluation

    The effect of CDX-0159 on tryptase

    Time frame: From Day 1 (before first dose) to Day 169 (last follow-up visit)

  8. Safety evaluation

    Assessment of immunogenicity by measuring the development of anti- CDX-0159 antibodies

    Time frame: From Day 1 (before dosing) to Day 169 (last follow-up visit)

07

Study locations

14 sites
  • Clinical Research Center of Alabama
    Birmingham, Alabama 35209, United States
  • Arizona Allergy & Immunology Research
    Gilbert, Arizona 85234, United States
  • Sarasota Clinical Research
    Sarasota, Florida 34239, United States
  • ForCare Clinical Research
    Tampa, Florida 33613, United States
  • Treasure Valley Medical Research
    Boise, Idaho 83706, United States
  • Midwest Allergy, Sinus and Asthma, SC
    Normal, Illinois 61761, United States
  • Dawes Fretzin Clinical Research
    Indianapolis, Indiana 46250, United States
  • Kanarek Allergy Asthma & Immunology
    Overland Park, Kansas 66211, United States
  • Bernstein Clinical Research Center, LLC
    Cincinnati, Ohio 45231, United States
  • Vital Prospects Clinical Research Institute, PC
    Tulsa, Oklahoma 74136-7028, United States
  • Asthma, Nasal Disease & Allergy Research Center of New England
    East Providence, Rhode Island 02914, United States
  • National Allergy and Asthma Research, LLC
    North Charleston, South Carolina 29420, United States
  • AARA Research
    Dallas, Texas 75231, United States
  • Charite University
    Berlin, 10117, Germany
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2020 to primary completion in Jan 2023, 27 months.

Of 15 phase 1 interventional studies under Chronic Urticaria, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 21. This study's 27 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2020
First posted
Sep 4, 2020
StartActual
Sep 24, 2020
Primary completionActual
Jan 17, 2023
CompletionActual
Jan 17, 2023
Last update
Jul 19, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 19, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04538794
Responsible party
Sponsor
First posted
Sep 4, 2020
Start date
Sep 24, 2020
Primary completion
Jan 17, 2023
Completion
Jan 17, 2023
Last update
Jul 19, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Barzolvolimab

Start the discussion